Jan 10, 2025 · Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal. ... (“Biogen”) on January 10, 2025, to acquire all outstanding shares of Sage not already owned by Biogen for $7.22 per share. The Company has not set a timetable for the review process, nor has it made ...

Nov 27, 2020 · Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S., excluding rights to zuranolone in Japan, Taiwan and South Korea; Sage Therapeutics to receive $1.525 billion in cash comprised of an upfront payment of $875 million and a $650 million equity investment as well as potential milestone ...

Sage and Biogen will continue to partner on ZURZUVAE® (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression (PPD) and will continue to work on their shared vision to help women suffering from PPD.

4 days ago · Sage Therapeutics Inc. is looking for a deal — but it’s not interested in the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.. The Cambridge ...

CAMBRIDGE Mass. – July 24, 2024 – Sage Therapeutics, Inc. (NASDAQ: Sage) and Biogen Inc. (NASDAQ: BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 (BIIB124) as a potential treatment in essential tremor (ET).

CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is ...

3 days ago · Sage Therapeutics and Biogen have a collaboration deal for the commercialization of Zurzuvae, which was approved for treating postpartum depression (PPD) in August 2023. The drug was commercially ...

4 days ago · Sage Therapeutics has officially rejected Biogen’s unsolicited takeover bid and will instead undergo a strategic review that could ultimately end up in a transaction of some kind. Sage’s board unanimously rejected the bid, arguing that the proposed $469 million significantly undervalued the company and is not in the best interest of ...

4 days ago · Sage’s board has stated it will consider “strategic alternatives” to maximise shareholder value. Credit: Bloomberg via Getty Images. Sage Therapeutics has rejected Biogen’s $469m takeover offer, with its board of directors unanimously concluding that …

Sep 26, 2024 · Sage and Biogen will continue to partner on ZURZUVAE® (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression (PPD) and will continue to work on their...